Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Financing
  6. Ipo

IPO

Thumbnail
May 06, 2022

For medtechs seeking deals, it’s hurry up and wait

Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.

Thumbnail
May 06, 2022

Bausch & Lomb takes a haircut

Article image
Vantage logo
April 07, 2022

Flotations tank in the first quarter

A correction – as long as it is not too severe – might not be a bad thing for the sector.

Article image
Vantage logo
March 18, 2022

Apexigen tests the market's appetite for CD40 agonism

Article image
Vantage logo
March 02, 2022

Zimvie gets a less than rapturous reception

Article image
Vantage logo
February 25, 2022

Crunch time for the Spac space

This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.

Article image
Vantage logo
January 20, 2022

Medical device groups float – then sink

Medtechs rushed for the markets last year, but had an uneasy time once there.

Article image
Vantage logo
December 16, 2021

Free to download now: Evaluate Vantage’s 2022 Preview

Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.

Article image
Vantage logo
October 05, 2021

Biotech listings show signs of a slowdown

2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.

Article image
Vantage logo
September 30, 2021

The heat is on for Oxford Nanopore

Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.

Article image
Vantage logo
September 07, 2021

Biopharma and medtech half-year review 2021

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.